Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial
Primary Purpose
Vomiting in Infants and/or Children
Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Ondansetron 4 MG
Sponsored by
About this trial
This is an interventional treatment trial for Vomiting in Infants and/or Children
Eligibility Criteria
Inclusion Criteria:
- Presence of at least 2 vomits in the last 4 hours.
- Negative tolerance test.
- Signature of the informed consent by the parents or legal guardians.
- Diagnosis of vomiting or diagnosis of acute gastroenteritis with vomiting.
- Patients weighing 15 kg or more.
Exclusion Criteria:
- Altered conciousness.
- Sospected acute abdomen (appendicitis, invaginations...).
- Suspicion or presence of obstructive disease.
- Known severe digestive disease (Chron´s disease, ulcerative colitis...).
- Suspected food poisoning.
- Allergy to any of the drugs used in the study.
- Severe dehydration.
- Bilious vomiting.
- Previous abdominal surgery.
- Pathology that may affective degree of hydration of the patient (kidney failure, hypoalbuminemia..).
- Admission requirement or intravenous rehydration for any reason.
- Concomitant use of apomorphine.
- In relation to the possible lengthening of the QT, patients with problems of previous arrhythmia should be excluded or that they are receiving concomitant medication that can lengthen the QT, that have electrolyte disturbances.
- Patients receiving other serotonergic drugs.
- Patients who have undergone a previous adenotonsillectomy.
- Patients with hypocalcemia and/or hypomagnesemia.
- Patients with hereditary fructose intolerance.
- Diabetes patients.
- Lactose intolerant patients.
- Patients with indication of the low sodium diets.
- Hypersensitivity to ondansetron or other antagonists of the 5-HT3.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Ondransetron
Habitual Clinical Practice
Arm Description
Administration of ondansetron
Habitual Clinical Practice
Outcomes
Primary Outcome Measures
Percentage of children who return to medical/pediatric consultation for de same episode
Is calculated percentage of children who return to medical/pediatric consultation for de same episode of vomiting
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04318847
Brief Title
Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial
Official Title
Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Unknown status
Study Start Date
October 10, 2021 (Anticipated)
Primary Completion Date
April 10, 2023 (Anticipated)
Study Completion Date
April 10, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Lizar Aguirre Pascasio
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This clinical trial is intended to evaluate the efficacy and safety of the administration of ondansetron in children with mild-moderate dehydration.
The target population will be children between 4 and 13 years old who present vomiting.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vomiting in Infants and/or Children
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
220 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Ondransetron
Arm Type
Experimental
Arm Description
Administration of ondansetron
Arm Title
Habitual Clinical Practice
Arm Type
No Intervention
Arm Description
Habitual Clinical Practice
Intervention Type
Drug
Intervention Name(s)
Ondansetron 4 MG
Intervention Description
Administration of ondansetron 4 mg or 8 mg according to weight
Primary Outcome Measure Information:
Title
Percentage of children who return to medical/pediatric consultation for de same episode
Description
Is calculated percentage of children who return to medical/pediatric consultation for de same episode of vomiting
Time Frame
An average of 24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
13 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Presence of at least 2 vomits in the last 4 hours.
Negative tolerance test.
Signature of the informed consent by the parents or legal guardians.
Diagnosis of vomiting or diagnosis of acute gastroenteritis with vomiting.
Patients weighing 15 kg or more.
Exclusion Criteria:
Altered conciousness.
Sospected acute abdomen (appendicitis, invaginations...).
Suspicion or presence of obstructive disease.
Known severe digestive disease (Chron´s disease, ulcerative colitis...).
Suspected food poisoning.
Allergy to any of the drugs used in the study.
Severe dehydration.
Bilious vomiting.
Previous abdominal surgery.
Pathology that may affective degree of hydration of the patient (kidney failure, hypoalbuminemia..).
Admission requirement or intravenous rehydration for any reason.
Concomitant use of apomorphine.
In relation to the possible lengthening of the QT, patients with problems of previous arrhythmia should be excluded or that they are receiving concomitant medication that can lengthen the QT, that have electrolyte disturbances.
Patients receiving other serotonergic drugs.
Patients who have undergone a previous adenotonsillectomy.
Patients with hypocalcemia and/or hypomagnesemia.
Patients with hereditary fructose intolerance.
Diabetes patients.
Lactose intolerant patients.
Patients with indication of the low sodium diets.
Hypersensitivity to ondansetron or other antagonists of the 5-HT3.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lizar Aguirre Pascasio, Dr
Phone
945007374
Email
LIZAR.AGUIRREPASCASIO@osakidetza.eus
12. IPD Sharing Statement
Learn more about this trial
Efficacy and Safety of the Administration of Ondansetron Versus Habitual Clinical Practice for the Treatment of Vomiting in Children With Mild and Moderate Dehydration: Randomized Clinical Trial
We'll reach out to this number within 24 hrs